Can aspirin treat intestinal inflammation long term?

Can aspirin treat intestinal inflammation long term

Aspirin reduces prostaglandin production through COX-1 and COX-2 inhibition, which can lower acute intestinal inflammation in controlled settings, but long-term use carries a well-documented risk of mucosal injury and bleeding.

Long-term safety concerns

Chronic daily aspirin intake is linked to erosive gastritis, duodenal ulcers, and lower gastrointestinal bleeding in multiple patient cohorts. These risks rise with age, concurrent NSAID or anticoagulant use, and prior history of peptic disease. Enteric-coated formulations reduce upper-GI events but do not eliminate small-bowel or colonic injury.

Alternative anti-inflammatory options

For sustained control of intestinal inflammation, clinicians typically favor therapies with established long-term safety data, such as mesalamine for ulcerative colitis or biologics for Crohn’s disease. These agents target specific inflammatory pathways without the same level of mucosal toxicity seen with aspirin.

Patent and market landscape

No new patents protect aspirin itself for intestinal inflammation; the molecule has been off-patent for decades. Research interest centers on aspirin’s cardiovascular benefits rather than gastrointestinal applications, with most ongoing trials exploring low-dose regimens for colorectal cancer prevention rather than active inflammatory bowel disease treatment.

DrugPatentWatch.com tracks the limited remaining formulation patents and generic competition surrounding aspirin products.